- Newmed Energy LP reported a net income of $147 million for the third quarter of 2024.
- The net income reflects a 25% increase compared to the same period last year.
- The company’s revenue for the quarter was $267.6 million, marking a growth of 9.7% year-over-year.
- Yossi Abu, the CEO, announced that the company aims to make a final investment decision on the Leviathan expansion project in the near future.
- Investment analysts provided one buy recommendation, no hold recommendations, and one sell recommendation for Newmed Energy LP.
A look at NewMed Energy LP Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores analysis, NewMed Energy LP is positioned for a promising long-term outlook. With a strong emphasis on dividend and momentum, the company demonstrates stability and potential for growth. The high score in dividend signifies a reliable income stream for investors, while the momentum score indicates positive market sentiment and potential for further price appreciation.
NewMed Energy LP, an energy company focusing on natural gas and condensate operations in Israel, shows a well-rounded performance across key factors such as growth and resilience. Although the value score is moderate, the overall outlook remains positive due to the company’s strong dividend policy and momentum in the market. With a solid foundation in exploration and production, NewMed Energy LP stands poised for sustainable growth in the energy sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
